RAD51B in Familial Breast Cancer

Liisa M. Pelttari(University of Helsinki), Sofia Khan(University of Helsinki), Mikko Vuorela(University of Oulu), Johanna I. Kiiski(University of Helsinki), Sara Vilske(University of Helsinki), Viivi Nevanlinna(University of Helsinki), Salla Ranta(University of Helsinki), Johanna Schleutker(University of Turku), Robert Winqvist(NordLab), Anne Kallioniemi(Tampere University), Thilo Dörk(Medizinische Hochschule Hannover), Natalia Bogdanova(Medizinische Hochschule Hannover), Jonine D. Figueroa(National Cancer Institute), Paul D.P. Pharoah(University of Cambridge), Marjanka K. Schmidt(The Netherlands Cancer Institute), Alison M. Dunning(University of Cambridge), Montserrat García‐Closas(Institute of Cancer Research), Manjeet K. Bolla(University of Cambridge), Joe Dennis(University of Cambridge), Kyriaki Michailidou(University of Cambridge), Qin Wang(University of Cambridge), John L. Hopper(The University of Melbourne), Melissa C. Southey(The University of Melbourne), Efraim H. Rosenberg(The Netherlands Cancer Institute), Peter A. Fasching(University of California, Los Angeles), Matthias W. Beckmann(Universitätsklinikum Erlangen), Julian Peto(London School of Hygiene & Tropical Medicine), Isabel dos‐Santos‐Silva(London School of Hygiene & Tropical Medicine), Elinor J. Sawyer(Guy's Hospital), Ian Tomlinson(Centre for Human Genetics), Barbara Burwinkel(German Cancer Research Center), Harald Surowy(German Cancer Research Center), Pascal Guénel(Université Paris-Sud), Thérèse Truong(Université Paris-Sud), Stig E. Bojesen(University of Copenhagen), Børge G. Nordestgaard(University of Copenhagen), Javier Benı́tez(Spanish National Cancer Research Centre), Anna González‐Neira(Spanish National Cancer Research Centre), Susan L. Neuhausen(City of Hope), Hoda Anton‐Culver(University of California, Irvine), Hermann Brenner(German Cancer Research Center), Volker Arndt(German Cancer Research Center), Alfons Meindl(Technical University of Munich), Rita K. Schmutzler(University of Cologne), Hiltrud Brauch(German Cancer Research Center), Thomas Brüning(Institute for Prevention and Occupational Medicine), Annika Lindblom(Karolinska Institutet), Sara Margolin(Karolinska Institutet), Arto Mannermaa(University of Eastern Finland), Jaana M. Hartikainen(University of Eastern Finland), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), kConFab/AOCS Investigators(The University of Melbourne), Laurien Van Dyck(KU Leuven), Hilde Janssen(Universität Hamburg), Jenny Chang-Claude(Universität Hamburg), Anja Rudolph(German Cancer Research Center), Paolo Radice(IFOM), Paolo Peterlongo(IFOM), Emily Hallberg(Mayo Clinic in Florida), Janet E. Olson(The University of Melbourne), Graham G. Giles(The University of Melbourne), Roger L. Milne(University of Southern California), Christopher A. Haiman(University of Southern California), Fredrick R. Schumacher(University of Southern California), Jacques Simard(Centre hospitalier universitaire de Québec), Martine Dumont(Oslo University Hospital), Vessela Kristensen(Oslo University Hospital), Anne‐Lise Børresen‐Dale(Oslo University Hospital), Wei Zheng(Vanderbilt University), Alicia Beeghly‐Fadiel(Vanderbilt University), Mervi Grip(Mount Sinai Hospital), Irene L. Andrulis(Mount Sinai Hospital), Gord Glendon(Mount Sinai Hospital), Peter Devilee(Leiden University Medical Center), Caroline Seynaeve(Erasmus MC Cancer Institute), Maartje J. Hooning(Erasmus MC), Margriet Collée(Erasmus MC), Angela Cox(University of Sheffield), Simon S. Cross(University of Cambridge), Mitul Shah(University of Cambridge), Robert Luben(German Cancer Research Center), Ute Hamann(German Cancer Research Center), Diana Torres(German Cancer Research Center), Anna Jakubowska(Pomeranian Medical University), Jan Lubiński(Mayo Clinic), Fergus J. Couch(Mayo Clinic), Drakoulis Yannoukakos(Institute of Cancer Research), Nick Orr(Institute of Cancer Research), Anthony J. Swerdlow(Institute of Cancer Research), Hatef Darabi(Karolinska Institutet), Jingmei Li(Karolinska Institutet), Kamila Czene(Karolinska Institutet), Per Hall(University of Cambridge), Douglas F. Easton(University of Helsinki), Johanna Mattson(University of Helsinki), Carl Blomqvist(University of Helsinki), Kristiina Aittomäki(University of Helsinki), Heli Nevanlinna(University of Helsinki)
PLoS ONE
May 5, 2016
Cited by 670Open Access
Full Text

Abstract

Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study was to investigate the role of RAD51B variants in breast cancer predisposition, particularly in the context of familial breast cancer in Finland. We sequenced the coding region of RAD51B in 168 Finnish breast cancer patients from the Helsinki region for identification of possible recurrent founder mutations. In addition, we studied the known rs999737, rs2588809, and rs1314913 SNPs and RAD51B haplotypes in 44,791 breast cancer cases and 43,583 controls from 40 studies participating in the Breast Cancer Association Consortium (BCAC) that were genotyped on a custom chip (iCOGS). We identified one putatively pathogenic missense mutation c.541C>T among the Finnish cancer patients and subsequently genotyped the mutation in additional breast cancer cases (n = 5259) and population controls (n = 3586) from Finland and Belarus. No significant association with breast cancer risk was seen in the meta-analysis of the Finnish datasets or in the large BCAC dataset. The association with previously identified risk variants rs999737, rs2588809, and rs1314913 was replicated among all breast cancer cases and also among familial cases in the BCAC dataset. The most significant association was observed for the haplotype carrying the risk-alleles of all the three SNPs both among all cases (odds ratio (OR): 1.15, 95% confidence interval (CI): 1.11-1.19, P = 8.88 x 10-16) and among familial cases (OR: 1.24, 95% CI: 1.16-1.32, P = 6.19 x 10-11), compared to the haplotype with the respective protective alleles. Our results suggest that loss-of-function mutations in RAD51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.


Related Papers